[2] MindMed was founded in May 2019 by Jamon Rahn, a Y-Combinator alumnus who worked at Uber, and Stephen Hurst, a 35-year veteran of the pharmaceutical industry.

[1][11] In a press release on June 9th, 2021 MindMed announced that Jamon Rahn was stepping down both as the CEO and as a director on the board, to be replaced by then CDO Robert Barrow.

Additionally, psilocybin taken after administering antidepressants for two weeks prior, was deemed safe, as well as reduced anxiety and blood pressure without hindering the psychedelic experience.

The university provided facilities and personnel for a Phase 1 study to evaluate the effects of two low doses of LSD on mood, sleep and neuroplasticity.

[20] The FDA has recently granted breakthrough therapy designation to MindMed's form of LSD (MM120) for the treatment of generalized anxiety disorder.